%0 Journal Article
%A Correa-Rodriguez, Maria
%A Callejas-Rubio, Jose-Luis
%A Rueda-Medina, Blanca
%A Rios-Fernandez, Raquel
%A Hera-Fernandez, Javier de la
%A Ortego-Centeno, Norberto
%T Clinical course of Covid-19 in a cohort of patients with Behçet disease.
%D 2021
%U http://hdl.handle.net/10668/22370
%X The implications of Covid-19 in patients with Behçet's disease (BD) are unknown. Patients with BD usually take long-term therapy with therapeutic agents that have been tested in Covid-19 patients. We aimed to assess the prevalence of Covid-19 in a cohort of patients with BD and investigate whether those patients with a long-term treatment with colchicine, tumor necrosis factor inhibitors (TNFi) or glucocorticoids are at reduced or increased prevalence of Covid-19 related clinical outcomes. A retrospective study was conducted among 244 patients with BD (86.1% females; mean age 43.95±11.11 years). Each participant completed an online questionnaire regarding demographics, medical conditions, dispensed colchicine, TNFi or oral glucocorticoids, Covid-19 infection, clinical symptoms and recovery. The prevalence of Covid-19 infection was 14.75%. Regarding dose of colchicine, the presence of ageusia was lower in patients taking 0.5mg/day of colchicine compared to those taking 1.5mg/day (p=0.021). The prevalence of dyspnea was significantly higher in patients taking TNFi compared with those without therapy (p=0.032). With regards to oral glucocorticoids, no significant differences were found. The prevalence of Covid-19 among patients with BD seems to be higher than that among the general population in Spain. Continuous TNFi therapy might increase the prevalence of worse clinical outcomes such as dyspnea; oral glucocorticoids and colchicine apparently provided no protection against the Covid-19 related clinical outcomes of patients with BD.
%K Behçet disease
%K COVID-19
%K Colchicina
%K Colchicine
%K Covid-19
%K Enfermedad de Behçet
%K Glucocorticoides
%K Glucocorticoids
%K Inhibidor del factor de necrosis tumoral alfa
%K Tumor necrosis factor alpha inhibitor
%~